Vanderbilt Network Lead Academic Participating Site for the NCTN

范德比尔特网络 (Vanderbilt Network) 主导 NCTN 学术参与网站

• 批准号: 9248776
• 负责人: JORDAN D BERLIN
• 金额: $ 41.02万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-17 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9248776
• 关键词: Advisory Committees; Affect; American College of Surgeons Oncology Group; Antineoplastic Agents; Area; Authorship; Award; Basic Science; Berlin; Breast; Budgets; Cancer Center; Cancer Patient; Caring; Clinical Investigator; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Collection; Complement; Country; Data; Detection; Development; Diagnosis; Discipline; Disease; Doctor of Medicine; Drug resistance; Early Detection Research Network; Eastern Cooperative Oncology Group; Ensure; Epigenetic Process; Faculty; Goals; Grant; Gynecologic Oncology Group; Health; Image; Institutes; Institution; Institutional Review Boards; Jordan; Lead; Leadership; Lung; Malignant Neoplasms; Malignant neoplasm of pancreas; Manuscripts; Medical; Medicine; Mentors; Mission; Mutation; National Clinical Trials Network; Patients; Phenotype; Physicians; Process; Proteome; Proteomics; Protocols documentation; Radiology Specialty; Research; Research Infrastructure; Research Personnel; Resource Sharing; Role; Science; Scientist; Site; Support Groups; System; Technology; Translational Research; Universities; Work; cancer genomics; design; drug development; drug discovery; improved outcome; inter-institutional; interest; medical specialties; meetings; member; multidisciplinary; next generation; programs; targeted treatment; tumor; web site

DESCRIPTION (provided by applicant): Vanderbilt-Ingram Cancer Center (VlCC) is a matrix cancer center within Vanderbilt University. VlCC trials been part of the cooperative group system for 24 years, as a member of the Eastern Cooperative Oncology Group, the Gynecologic Oncology Group (GOG) and the American College of Surgeons Oncology Group (ACOSOG). In this role, we have integrated our physicians into leadership roles and our science into the clinical trials and accrued patients into trials. The VlCC selected Jordan Berlin, MD, as PI to lead the efforts of the institution to integrate its scientific, academic and patient resourcs into the new NCTN. He has been involved extensively In the cooperative groups in both clinical trials and leadership. He has also been a successful mentor. To maintain a broad representation across medical disciplines and disease interests, two leadership boards were created. The internal advisory board (lAB) assures the optimum use of the grant such as budget review, assuring multidisciplinary involvement and participation throughout the NCTN while the NCTN Executive Committee (NEC) implements operational functions such as trial opening, accrual, and mentoring. Both the lAB and NEC will work to integrate VlCC science into the NCTN. The VlCC Clinical Trials Shared Resource and its NCTN team will ensure that regulatory and biospecimen/radiology data submissions are timely and highly accurate. VlCC has a long track record of leadership, both scientific and administrative, within the cooperative groups, integrating basic science into clinical trials and helping junior faculty in trial development. VlC brings great strengths to the NCTN including two SPORE grants, two EDRN grants, a world class Institute of Imaging Science, advanced capabilities in proteomics and a superb Center for Quantitative Sciences. Our Personalized Cancer Medicine Initiative is dedicated to answering Provocative Question B5 (How does the order in which mutations or epigenetic changes occur alter cancer phenotypes or affect the efficacy of targeted therapies?), and bringing the data from drug resistance-associated mutations into clinical trials. This is complemented by MyCancerGenome, a website that not only informs physicians on the latest in cancer genomics, but also the availability of trials for patients whose tumors harbor actionable genetic alterations The team of VlCC scientists, academic leaders and junior Investigators will significantly contribute to the NCTN goals and, as a result, improve the outcomes for cancer patients.

描述（由申请人提供）：范德比尔特-英格拉姆癌症中心 (VlCC) 是范德比尔特大学内的一个矩阵癌症中心。 24 年来，VlCC 试验一直是合作小组系统的一部分，是东部肿瘤合作小组、妇科肿瘤小组 (GOG) 和美国外科医生学会肿瘤小组 (ACOSOG) 的成员。在这个角色中，我们将我们的医生纳入领导角色，将我们的科学纳入临床试验，并将患者纳入试验。 VlCC 选择 Jordan Berlin 医学博士作为 PI，领导该机构将其科学、学术和患者资源整合到新的 NCTN 中。他广泛参与合作小组的临床试验和领导工作。他也是一位成功的导师。为了保持跨医学学科和疾病利益的广泛代表性，成立了两个领导委员会。内部顾问委员会 (LAB) 确保预算审查等赠款的最佳使用，确保整个 NCTN 的多学科参与和参与，而 NCTN 执行委员会 (NEC) 则负责实施试验开放、应计和指导等运营职能。 LAB 和 NEC 都将致力于将 VlCC 科学纳入 NCTN。 VlCC 临床试验共享资源及其 NCTN 团队将确保及时且高度准确地提交监管和生物样本/放射学数据。 VlCC 在合作小组中拥有长期的科学和行政领导记录，将基础科学融入临床试验并帮助初级教师进行试验开发。 VlC 为 NCTN 带来了巨大的优势，包括两项 SPORE 资助、两项 EDRN 资助、世界一流的成像科学研究所、先进的蛋白质组学能力以及一流的定量科学中心。我们的个性化癌症医学计划致力于回答具有挑战性的问题 B5（突变或表观遗传变化发生的顺序如何改变癌症表型或影响靶向治疗的疗效？），并将耐药相关突变的数据引入临床试验。 MyCancerGenome 对此进行了补充，该网站不仅向医生通报癌症基因组学的最新信息，还向肿瘤携带可操作基因改变的患者提供试验的可用性。VlCC 科学家、学术领袖和初级研究人员组成的团队将为癌症基因组学的发展做出重大贡献。 NCTN 的目标是改善癌症患者的治疗结果。